News & Updates

Repeat transarterial chemoembolization (TACE) is not recommended for patients with hepatocellular carcinoma (HCC) who have persistent liver function deterioration after initial TACE, particularly if they have suboptimal baseline liver function or excessive tumour burden, according to researchers from the Chinese University of Hong Kong (CUHK).

Genome-guided therapy has improved survival outcomes and reduced toxicities and complications from cytotoxic chemotherapy, thereby enhancing the quality of life of patients with non-small-cell lung cancer (NSCLC). At an industry-sponsored symposium, Dr Molly Li of the Department of Clinical Oncology, the Chinese University of Hong Kong, and Professor Yoon-La Choi of the Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea, focused on the clinical importance and challenges of detecting EGFR exon 20 insertions (exon20ins) in NSCLC patients and discussed the latest clinical evidence on EGFR exon20ins–targeted treatments.

De-escalation of chemotherapy dose and trastuzumab duration may not increase the risk of distant relapse or death in patients with ERBB2-positive (also referred to as HER2-positive) early breast cancer and tumour infiltrating lymphocyte (TIL) levels of ≥20 percent, according to a 10-year analysis of the phase III ShortHER trial.